May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

Lung disease warning for Lilly breast cancer drug in Japan
Eli Lilly and Co. (NYSE:LLY) told BioCentury it has updated the Japanese label of breast cancer drug Verzenio abemaciclib to include a warning for interstitial lung disease/pneumonitis following reports of several postmarketing cases in the country.

In other Lilly news, the pharma said its half-priced authorized generic version of Humalog insulin lispro is now available for order in pharmacies. The generic has a wholesale acquisition cost (WAC) of $137.35 for a 10 mL vial; Humalog's WAC is $274.70 (see "Lilly Offers Cheaper Insulin, Pressuring Competitors")...